Cargando…
Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study
BACKGROUND: Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk factors. Controlling these factors requires lifestyle modifications alongside utilisation of anti-diabetic medications. Different glucose lowering [(biguanides (BIGs), sulfonylureas (SUAs), thiazolidinedion...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587509/ https://www.ncbi.nlm.nih.gov/pubmed/28879491 http://dx.doi.org/10.1186/s40169-017-0162-5 |
_version_ | 1783261996268912640 |
---|---|
author | Adua, Eric Roberts, Peter Sakyi, Samuel Asamoah Yeboah, Francis Agyemang Dompreh, Albert Frimpong, Kwasi Anto, Enoch Odame Wang, Wei |
author_facet | Adua, Eric Roberts, Peter Sakyi, Samuel Asamoah Yeboah, Francis Agyemang Dompreh, Albert Frimpong, Kwasi Anto, Enoch Odame Wang, Wei |
author_sort | Adua, Eric |
collection | PubMed |
description | BACKGROUND: Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk factors. Controlling these factors requires lifestyle modifications alongside utilisation of anti-diabetic medications. Different glucose lowering [(biguanides (BIGs), sulfonylureas (SUAs), thiazolidinediones (TNZ)], lipid lowering (statins), and anti-hypertensive medicines [angiotensin converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin II receptor blockers (ARBs) and central acting drugs (CADs)] have been approved for controlling hyperglycaemia, dyslipidaemia and hypertension respectively. Here, we examined factors that characterise T2DM and explored the response to medication therapy among T2DM patients. METHODS: This prospective cohort study recruited 241 T2DM patients reporting at a clinic in Ghana, from January through to August, 2016. Each patient’s demographic, medications and anthropometric data was obtained while information on medication adherence was captured using Morisky adherence scale-8 (MMAS-8). Fasting blood samples were collected for biochemical analysis. RESULTS: The mean age of participants was 57.82 years for baseline and six-month follow-up. Physical activity differed at baseline and follow up (p < 0.05) but not body mass index (BMI). BIG alone, or in combination with SUA and TNZ did not improve glycaemic status at follow up (p > 0.05). Many participants using either ACEI or ARB were able to control their blood pressures. Among dyslipidaemia patients under statin treatment, there was an improved lipid profile at follow-up. CONCLUSIONS: Statin medications are effective for reducing dyslipidaemia in T2DM patients. However, control of modifiable risk factors, particularly blood glucose and to a lesser degree blood pressure is suboptimal. Addressing these will require concomitant interventions including education on medication adherence and correct dietary plans, lifestyle modifications and physical activity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40169-017-0162-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5587509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-55875092017-09-27 Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study Adua, Eric Roberts, Peter Sakyi, Samuel Asamoah Yeboah, Francis Agyemang Dompreh, Albert Frimpong, Kwasi Anto, Enoch Odame Wang, Wei Clin Transl Med Research BACKGROUND: Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk factors. Controlling these factors requires lifestyle modifications alongside utilisation of anti-diabetic medications. Different glucose lowering [(biguanides (BIGs), sulfonylureas (SUAs), thiazolidinediones (TNZ)], lipid lowering (statins), and anti-hypertensive medicines [angiotensin converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin II receptor blockers (ARBs) and central acting drugs (CADs)] have been approved for controlling hyperglycaemia, dyslipidaemia and hypertension respectively. Here, we examined factors that characterise T2DM and explored the response to medication therapy among T2DM patients. METHODS: This prospective cohort study recruited 241 T2DM patients reporting at a clinic in Ghana, from January through to August, 2016. Each patient’s demographic, medications and anthropometric data was obtained while information on medication adherence was captured using Morisky adherence scale-8 (MMAS-8). Fasting blood samples were collected for biochemical analysis. RESULTS: The mean age of participants was 57.82 years for baseline and six-month follow-up. Physical activity differed at baseline and follow up (p < 0.05) but not body mass index (BMI). BIG alone, or in combination with SUA and TNZ did not improve glycaemic status at follow up (p > 0.05). Many participants using either ACEI or ARB were able to control their blood pressures. Among dyslipidaemia patients under statin treatment, there was an improved lipid profile at follow-up. CONCLUSIONS: Statin medications are effective for reducing dyslipidaemia in T2DM patients. However, control of modifiable risk factors, particularly blood glucose and to a lesser degree blood pressure is suboptimal. Addressing these will require concomitant interventions including education on medication adherence and correct dietary plans, lifestyle modifications and physical activity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40169-017-0162-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-09-07 /pmc/articles/PMC5587509/ /pubmed/28879491 http://dx.doi.org/10.1186/s40169-017-0162-5 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Adua, Eric Roberts, Peter Sakyi, Samuel Asamoah Yeboah, Francis Agyemang Dompreh, Albert Frimpong, Kwasi Anto, Enoch Odame Wang, Wei Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study |
title | Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study |
title_full | Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study |
title_fullStr | Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study |
title_full_unstemmed | Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study |
title_short | Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study |
title_sort | profiling of cardio-metabolic risk factors and medication utilisation among type ii diabetes patients in ghana: a prospective cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587509/ https://www.ncbi.nlm.nih.gov/pubmed/28879491 http://dx.doi.org/10.1186/s40169-017-0162-5 |
work_keys_str_mv | AT aduaeric profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy AT robertspeter profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy AT sakyisamuelasamoah profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy AT yeboahfrancisagyemang profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy AT domprehalbert profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy AT frimpongkwasi profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy AT antoenochodame profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy AT wangwei profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy |